0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Ligand nanovectorization using graphene to target cellular death receptors of cancer cell.

      1 , 1 , 1
      Proteins
      Wiley
      anticancer ligand, graphene, nanovectorization, simulation

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is nowadays envisaged as a natural cytokine useful in nanomedicine to eradicate the cancer cells and not the healthy surrounding ones. However, it suffers from cell resistance and strong dispersion in body to prove its efficiency. The understanding at the molecular level of the TRAIL interaction with death receptors (DRs) on cancer cells is thus of fundamental importance to improve its action. We demonstrate here via molecular simulations that TRAIL can bind to its both agonistic DRs (ie, DR4 and DR5) with a preference for DR4. In this study, the role of a graphene nanoflake as a potential cargo for TRAIL is examined. Furthermore, both TRAIL self-assembling and TRAIL affinity when adsorbed on graphene are considered to enhance efficacy toward the targeted cancer cell. Our modelization results show that TRAIL can bind to DR4 and DR5 when transported by graphene nanoflake, as a proof of concept.

          Related collections

          Author and article information

          Journal
          Proteins
          Proteins
          Wiley
          1097-0134
          0887-3585
          Jan 2020
          : 88
          : 1
          Affiliations
          [1 ] Laboratoire de Nanomédecine, Imagerie et Thérapeutique, EA4662, Université Bourgogne-Franche-Comté (UFR Sciences et Techniques, UFR Sciences Médicales et Pharmaceutiques), Centre Hospitalier Universitaire de Besançon, Besançon, France.
          Article
          10.1002/prot.25772
          31294850
          1f427e7f-18f2-4ff1-87e9-2da7aaabad4c
          History

          nanovectorization,simulation,graphene,anticancer ligand
          nanovectorization, simulation, graphene, anticancer ligand

          Comments

          Comment on this article